Innoviva’s Upside Edge Amid a Deep‑Drawdown Legacy

Why the current Bull‑HighVol regime could amplify gains while risk flags linger

INVA Innoviva, Inc.

In this report

01

Returns Overview

Period returns, alpha, cumulative performance, distributions

P. 2-3

→

02

Volatility Analysis

Annualized volatility, downside deviation, drawdowns

P. 4-5

→

03

Beta & Correlation

Trailing, upside, downside beta, systematic risk

P. 6-7

→

04

Risk-Adjusted Returns

Sharpe, Sortino, Calmar, Information, Treynor

P. 8-9

→

05

Market Regime Analysis

Bull/bear behavior, capture ratios

P. 10-11

→

06

Investment Highlights & Risk Summary

Executive summary, risk flags, rankings

P. 12-13

→

Returns Overview

Innoviva, Inc. (INVA) — Return Performance

Innoviva, Inc. (INVA) delivered a mixed return profile across horizons, posting a 5.14% gain over the past month while generating 7.73% alpha versus its healthcare sector benchmark. The stock’s longer‑term performance was stronger, with cumulative returns of 76.9% over three years and 67.93% over five years; however, its alpha turned negative in those periods (−10.99% and −3.88% respectively), indicating that the outperformance was largely driven by broader sector momentum rather than stock‑specific skill.

Period Returns vs S&P 500 & XLV

Monthly Returns Heatmap

INVA

Short‑term returns were modestly positive, but the 1‑month alpha of 7.73% suggests a brief outperformance that was not sustained, as the 3‑month period showed a -3.35% loss and negative alpha of -16.45%. Over medium horizons (1‑year to 2‑years), INVA produced solid absolute returns (12.1% YTD, 37.32% over two years) with modest or slightly positive sector‑adjusted performance, highlighting a divergence where the stock outperformed its own baseline but lagged the sector. The strongest upside came in the 3‑year window, delivering 76.9% total return despite a sizable negative alpha, underscoring that sector strength rather than company‑specific drivers powered the gains.

Returns Overview

Innoviva, Inc. (INVA) — Return Charts

Volatility Analysis

Innoviva, Inc. (INVA) — Volatility Profile

Innoviva, Inc. (INVA) exhibits markedly higher price variability than the broader market, with an annualized volatility of 38.57% versus the S&P 500’s 17.78%, indicating more than double the typical price swings. The stock’s downside risk metrics reinforce this view: a downside deviation of 28.28% and a historic maximum drawdown of -64.72% over a multi‑year period illustrate both deep losses and prolonged recovery, the latter taking over three years to regain its prior peak. While recent short‑term volatility (60‑day at 23.07%) sits below the long‑run average, the 252‑day figure (28.81%) remains elevated relative to the annualized level, suggesting that current market conditions have temporarily tempered but not eliminated the inherent risk profile.

Volatility Metrics

INVA

The stock’s volatility is more than twice that of the S&P 500, reflecting a high‑beta exposure to sector‑specific catalysts and earnings uncertainty. Downside deviation of 28.28% signals that negative returns are pronounced, while the -64.72% max drawdown—spanning from June 2015 to September 2015 with a recovery only completed in January 2019—highlights both depth and duration of adverse price moves. The 60‑day volatility of 23.07% is comfortably below the long‑term annualized figure, indicating a short‑run cooling period; however, the 252‑day volatility remains elevated at 28.81%, underscoring that medium‑term risk has not fully subsided.

INVA’s annualized volatility (38.57%) is more than double the S&P 500 benchmark.
Downside deviation of 28.28% points to pronounced negative return variability.
The historic max drawdown of -64.72% lasted over three years to recover, indicating severe and persistent downside risk.
Current 60‑day volatility (23.07%) is below the long‑term average, suggesting a temporary easing of short‑run price swings.
252‑day volatility (28.81%) remains high relative to both the annualized figure and market benchmark.

Positive Characteristics
Short‑term volatility has moderated, with the 60‑day measure below the long‑run average, offering a brief window of reduced risk.
Despite overall heightened risk, the stock’s recovery from its deepest drawdown demonstrates resilience over extended horizons.

Volatility Analysis

Innoviva, Inc. (INVA) — Volatility & Drawdown Charts

Beta & Correlation

Innoviva, Inc. (INVA) — Beta Profile

Innoviva, Inc. exhibits a trailing beta of 0.768 versus the S&P 500, placing it in the defensive range (<0.8). This suggests that the stock tends to move less than the broad market on average, providing a modest cushion during equity sell‑offs. However, its sector beta of 0.862 relative to the Healthcare index (XLV) indicates slightly higher sensitivity to industry‑specific dynamics than to the overall market, implying that healthcare trends drive more of the price variance than general market sentiment. The asymmetric upside/downside betas—0.724 on the upside and 0.812 on the downside—reveal a modest tilt toward greater volatility during market declines, a key consideration for risk‑averse investors. An R-squared of 12.5% against the S&P 500 means that only a small fraction of Innoviva’s price movements are explained by broad market factors, leaving 87.5% as idiosyncratic risk that can be diversified away in a well‑balanced portfolio.

Beta & Correlation Metrics

INVA

The trailing beta of 0.768 classifies Innoviva as defensive, indicating lower-than-market price swings during bullish cycles and limited participation in upside rallies. The downside beta of 0.812 exceeds the upside figure, signaling that losses tend to be marginally larger when the market falls—a nuance that risk managers should factor into stress‑testing scenarios. With a sector beta of 0.862, Innoviva’s exposure to healthcare-specific drivers is more pronounced than its overall market exposure, suggesting that sector news (e.g., drug approvals or regulatory changes) will have a relatively larger impact on the stock than macroeconomic shifts.

Trailing beta of 0.768 places Innoviva in a defensive position relative to the S&P 500.
Downside beta (0.812) exceeds upside beta (0.724), indicating slightly higher sensitivity to market declines.
R-squared of 12.5% shows that only a modest portion of price movement is driven by broad market factors; most risk is idiosyncratic.
Sector beta of 0.862 > market beta, highlighting greater exposure to healthcare industry dynamics than to overall equity market movements.
Systematic risk accounts for 12.5% of total variance, while idiosyncratic risk dominates at 87.5%.

Positive Characteristics
Defensive market beta provides downside protection in broader market sell‑offs.
High proportion of idiosyncratic risk offers diversification benefits within multi‑asset portfolios.
Sector beta above market beta suggests the stock can capture upside from favorable healthcare trends.

Beta & Correlation

Innoviva, Inc. (INVA) — Rolling Beta

Positive Notes

Defensive market beta provides downside protection in broader market sell‑offs.

High proportion of idiosyncratic risk offers diversification benefits within multi‑asset portfolios.

Sector beta above market beta suggests the stock can capture upside from favorable healthcare trends.

Risk-Adjusted Returns

Innoviva, Inc. (INVA) — Risk-Adjusted Performance

Innoviva, Inc. (INVA) delivers modest risk-adjusted returns, with a Sharpe ratio of 0.229 indicating that its total return exceeds the risk‑free rate by only about 22.9% per unit of total volatility—a level well below the benchmark of 1.0 for acceptable performance. The Sortino ratio of 0.313 is higher than the Sharpe, suggesting that downside volatility is lower relative to overall volatility and that the stock’s return profile is somewhat more favorable when focusing on negative deviations. However, the Calmar ratio of 0.193 reflects a weak return‑to‑drawdown relationship, implying that periods of loss have eroded much of the upside gains, while the near‑zero Information ratio (-0.009) signals an absence of consistent alpha generation relative to a benchmark.

Risk-free rate: 3.63% (Fed Funds Rate)

Risk-Adjusted Metrics

INVA

The Sharpe ratio of 0.229 places Innoviva well under typical thresholds for attractive risk‑adjusted performance, indicating that the stock’s excess return is modest relative to its total volatility. In contrast, the Sortino ratio of 0.313 exceeds the Sharpe, highlighting a comparatively milder downside risk and suggesting that investors may experience fewer severe losses than the overall volatility would imply. The Calmar ratio of 0.193 points to significant drawdowns; a higher figure would be needed to demonstrate resilience against market troughs, and this low value signals that past declines have been relatively deep compared with cumulative returns.

Sharpe ratio (0.229) is far below the 1.0 benchmark, indicating limited excess return per unit of total risk.
Sortino ratio (0.313) exceeds Sharpe, revealing a more favorable downside‑risk profile than implied by overall volatility.
Calmar ratio (0.193) suggests that worst drawdowns have substantially offset returns, highlighting vulnerability to market declines.
Information ratio (-0.009) shows no consistent alpha generation relative to a benchmark index.

Positive Characteristics
The higher Sortino versus Sharpe indicates that downside volatility is relatively contained.
A Treynor ratio of 11.525 reflects strong return per unit of systematic (beta) risk, implying the stock has been rewarded for market exposure.

Risk-Adjusted Returns

Innoviva, Inc. (INVA) — Rolling Sharpe & Sortino

Positive Notes

The higher Sortino versus Sharpe indicates that downside volatility is relatively contained.

A Treynor ratio of 11.525 reflects strong return per unit of systematic (beta) risk, implying the stock has been rewarded for market exposure.

Market Regime Analysis

Innoviva, Inc. (INVA) — Regime Behavior

Innoviva, Inc. demonstrates a pronounced sensitivity to market volatility within bullish cycles, delivering an average monthly return of 2.06% during Bull-HighVol periods—substantially higher than the modest 0.45% achieved in calm Bull-LowVol environments. In contrast, its performance deteriorates sharply when markets decline under low‑volatility conditions, posting a -0.91% average return in Bear-LowVol regimes, while it barely breaks even (+0.06%) during turbulent Bear-HighVol phases. The stock’s upside capture of 79.7% and downside capture of 51.6% yield a capture ratio of 1.55, indicating that Innoviva captures roughly one‑and‑a‑half times more upside than downside relative to the S&P 500, a favorable asymmetry for investors seeking growth with moderated downside risk.

Current Market Regime: Bull-HighVol

Bull-LowVol = calm uptrend • Bull-HighVol = volatile uptrend • Bear-LowVol = orderly decline • Bear-HighVol = crisis

Regime Returns & Capture Ratios

INVA

During Bull-HighVol regimes, Innoviva’s average monthly gain of 2.06% reflects its ability to capitalize on heightened market activity, likely driven by sector‑specific catalysts and increased investor appetite for riskier assets. However, the modest 0.45% return in Bull-LowVol periods suggests limited upside when volatility subsides, implying that the stock relies on market turbulence to generate momentum. In Bear-LowVol environments, the -0.91% average decline signals vulnerability during orderly downtrends, whereas the near‑flat performance (+0.06%) in Bear-HighVol regimes indicates some defensive resilience when markets are volatile but falling, though not enough to offset broader downside pressures.

Market Regime Analysis

Innoviva, Inc. (INVA) — Regime & Capture Charts

Regime Timeline

Innoviva excels in volatile bullish markets, delivering over 2% average monthly returns.
The stock underperforms in calm bearish periods, with a negative -0.91% return.
Upside capture of 79.7% combined with downside capture of 51.6% produces a capture ratio of 1.55, signifying favorable risk‑adjusted upside potential.
Current Bull-HighVol regime aligns with Innoviva’s strongest performance profile, supporting continued outperformance if volatility persists.
Bear-HighVol resilience is modest; the stock does not provide strong defensive characteristics in downturns.

Positive Characteristics
Strong upside capture during volatile uptrends highlights growth potential when market sentiment is heightened.
Capture ratio above 1.0 indicates the stock gains more on the upside than it loses on the downside relative to the benchmark.

Investment Highlights & Risk Summary

Innoviva, Inc. (INVA) — Summary & Implications

Innoviva, Inc. (INVA) delivered a 12.1% total return over the past year, yet its performance lagged the broader market by 6.9 percentage points, generating a negative alpha of -6.9% versus the S&P 500 and -2.43% versus the healthcare sector ETF (XLV). The stock exhibits elevated volatility at an annualized 38.57%, far above the S&P 500's 17.1%, and has experienced a severe maximum drawdown of -64.72%, flagging significant capital loss risk. Risk‑adjusted metrics are modest, with a Sharpe ratio of 0.229 and a Sortino ratio of 0.313, indicating limited excess return per unit of total or downside risk. Nonetheless, the upside capture of 79.7% versus a downside capture of 51.6% suggests that INVA participates in market gains while cushioning losses, and its beta of 0.768 points to lower systematic risk relative to the market.

Summary Dashboard

Investment Highlights

Annualized volatility of 38.57% reflects strong price movement, offering potential for short‑term trading opportunities.
Upside capture ratio of 79.7% combined with downside capture of 51.6% yields a capture ratio above 1.0, indicating the stock tends to outperform on market rallies while limiting losses in downturns.
Beta of 0.768 suggests lower sensitivity to overall market swings, providing a defensive tilt within an equity‑heavy portfolio.

Risk-Return Rankings

INVA HIGH

High volatility and deep drawdown risk outweigh modest upside capture and low beta.

Strength: Upside capture of 79.7% with downside capture only 51.6%, limiting losses in market declines.

Concern: Maximum drawdown of -64.72% signals substantial capital loss potential.

Key Takeaways

INVA's negative alpha (-6.9% vs S&P, -2.43% vs XLV) indicates underperformance relative to both the market and its sector.
The stock's Sharpe (0.229) and Sortino (0.313) ratios are well below the benchmark of 1.0, reflecting weak risk‑adjusted returns.
Elevated volatility (38.57%) and a historic drawdown of -64.72% highlight significant downside risk for investors.
Despite high risk, the low beta (0.768) and favorable capture profile provide some defensive characteristics.

PORTFOLIO IMPLICATIONS

Innoviva's risk profile is characterized by high volatility and deep drawdown potential, making it suitable primarily for investors with a high risk tolerance seeking asymmetric upside in a healthcare allocation. Its lower beta and downside capture can add modest diversification benefits to a broader equity portfolio, but the negative alpha and weak risk‑adjusted metrics suggest it should occupy a limited position size, preferably as a satellite holding rather than a core exposure.

INVA

Related Reports

Visit finexus.net/reports for more reports

Report written 2026-06-07 • Finexus

Disclaimer

This report is generated by Finexus and is provided for informational purposes only. It does not constitute investment advice, a recommendation, or an offer or solicitation to buy or sell any security.

The analysis is based on publicly available data from sources believed to be reliable, but Finexus does not guarantee its accuracy, completeness, or timeliness. Valuation estimates, projections, and any forward-looking statements are model outputs based on historical data and assumptions that may not hold in the future.

Past performance is not indicative of future results. Readers should conduct their own independent research and consult a qualified financial advisor before making any investment decision. Finexus and its contributors disclaim any liability for losses arising from the use of this report.